Physician profile
Robert J Gary
NPI 1972563427
$3,612.32
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,080 · 2020: $362 · 2021: $1,120 · 2022: $991 · 2023: $39.36 · 2024: $18.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $58.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $58.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $899.84 | 2019-2022 | |
| Astellas Pharma US INC | $409.25 | 2019-2024 | Myrbetriq |
| Janssen Biotech, INC. | $233.82 | 2019-2022 | |
| Myovant Sciences INC. | $213.67 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $201.75 | 2019-2020 | |
| Teleflex LLC | $173.14 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $155.58 | 2019-2022 | |
| Abbvie INC. | $148.26 | 2022-2023 | |
| Myriad Genetic Laboratories, INC. | $146.17 | 2020-2022 | |
| Neotract INC. | $109.64 | 2019 | |
| Boston Scientific Corporation | $100.24 | 2019-2022 | |
| Blue Earth Diagnostics | $72.38 | 2019-2021 | |
| Tolmar Pharmaceuticals, INC. | $61.99 | 2021-2022 | |
| Genzyme Corporation | $60.35 | 2019 | |
| Allergan, INC. | $60.09 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $59.75 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $55.44 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $49.31 | 2022 | |
| Convatec INC. | $48.80 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $47.25 | 2022 | |
| Endo Pharmaceuticals INC. | $43.00 | 2019-2021 | |
| Amgen INC. | $35.94 | 2019 | |
| Urovant Sciences INC | $35.41 | 2022 | |
| Antares Pharma, INC. | $33.95 | 2021 | |
| Coloplast Corp | $30.92 | 2022 | |
| Pfizer INC. | $30.86 | 2022 | |
| Clarus Therapeutics INC. | $23.71 | 2021 | |
| Baxter Healthcare | $16.24 | 2021 | |
| Verity Pharmaceuticals INC. | $16.23 | 2022 | |
| Clinigen, INC. | $14.73 | 2020 | |
| Dentsply Ih INC. | $12.47 | 2019 | |
| Foundation Medicine, INC. | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.